Travere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Misses Estimates By $0.15 EPS

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15), Zacks reports. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%.

Travere Therapeutics Trading Up 1.1 %

NASDAQ TVTX traded up $0.25 during trading on Thursday, hitting $23.58. The stock had a trading volume of 1,320,310 shares, compared to its average volume of 1,582,407. Travere Therapeutics has a one year low of $5.12 and a one year high of $25.29. The stock has a 50 day simple moving average of $19.47 and a 200 day simple moving average of $16.43. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -5.18 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71.

Insider Activity

In related news, CAO Sandra Calvin sold 54,244 shares of the firm's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the transaction, the chief accounting officer now owns 54,410 shares of the company's stock, valued at $1,360,250. This trade represents a 49.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Eric M. Dube sold 11,375 shares of Travere Therapeutics stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $24.04, for a total transaction of $273,455.00. Following the sale, the chief executive officer now owns 419,173 shares of the company's stock, valued at $10,076,918.92. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 218,425 shares of company stock valued at $4,674,259. 3.75% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have issued reports on TVTX shares. Scotiabank lifted their price target on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 12th. Canaccord Genuity Group lifted their target price on Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Barclays increased their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on Travere Therapeutics in a report on Friday, January 10th. They set an "overweight" rating on the stock. Finally, HC Wainwright raised their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Travere Therapeutics has an average rating of "Moderate Buy" and an average price target of $27.77.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.